Regeneron Pharmaceuticals, Inc. (REGN) shareholders
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$955.47+4.28 (+0.45%)
Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
88.5%
92M of 103M shares
Institutional holders
1,332
122 new, 168 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 134 sales
Net sold $57.93M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,629,707 | 8.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 7,660,810 | 7.37% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of REGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,113,506 | 8.81% | $5.68B | +165,771 | 0.08% |
| Vanguard Capital Management LLC | 6,629,759 | 6.41% | $4.13B | −25,154 | 0.09% |
| Dodge & Cox | 4,871,137 | 4.71% | $3.04B | +412,899 | 1.59% |
| State Street Corp | 4,834,688 | 4.67% | $3.01B | +170,210 | 0.09% |
| Invesco Ltd. | 3,940,665 | 3.81% | $2.46B | +35,556 | 0.19% |
| JPMorgan Chase & Co | 3,774,199 | 3.65% | $2.38B | −537,607 | 0.13% |
| Vanguard Portfolio Management LLC | 3,175,313 | 3.07% | $1.98B | +1,454,539 | 0.09% |
| Franklin Resources Inc | 2,771,839 | 2.68% | $1.73B | +49,768 | 0.37% |
| Geode Capital Management, LLC | 2,625,810 | 2.54% | $1.63B | +18,078 | 0.09% |
| Nuveen, LLC | 2,019,974 | 1.95% | $1.26B | −45,090 | 0.30% |
| Loomis Sayles & Co L P | 1,859,172 | 1.80% | $1.16B | −53,138 | 1.45% |
| Price T Rowe Associates Inc /Md/ | 1,529,709 | 1.48% | $953.84M | −647,818 | 0.10% |
| Morgan Stanley | 1,397,712 | 1.35% | $871.53M | +78,383 | 0.05% |
| Bank Of America Corp /De/ | 1,291,053 | 1.25% | $805.02M | +101,469 | 0.05% |
| Wellington Management Group Llp | 1,270,087 | 1.23% | $791.95M | −567,372 | 0.14% |
| Norges Bank | 1,172,808 | 1.13% | $731.29M | New | 0.07% |
| Goldman Sachs Group Inc | 1,163,191 | 1.12% | $725.30M | −137,367 | 0.06% |
| Aqr Capital Management LLC | 1,126,080 | 1.09% | $702.16M | −104,928 | 0.24% |
| Amundi | 1,013,540 | 0.98% | $631.98M | +3,742 | 0.15% |
| Northern Trust Corp | 916,467 | 0.89% | $571.45M | −25,474 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,332 | 92M | 88.5% | 122 / 485 | 538 / 168 | 9M | 8M |
| Q1 2026 | 1,399 | 91M | 87.5% | 137 / 575 | 464 / 102 | 16M | 8M |
| Q4 2025 | 1,386 | 92M | 88.8% | 272 / 501 | 457 / 107 | 13M | 12M |
| Q3 2025 | 1,244 | 91M | 88.2% | 173 / 488 | 418 / 112 | 12M | 10M |
| Q2 2025 | 1,202 | 90M | 86.8% | 134 / 443 | 476 / 207 | 10M | 13M |
| Q1 2025 | 1,290 | 93M | 90.2% | 141 / 527 | 452 / 148 | 7M | 7M |
| Q4 2024 | 1,317 | 94M | 90.5% | 169 / 479 | 494 / 215 | 9M | 17M |
| Q3 2024 | 1,391 | 101M | 98.0% | 142 / 541 | 464 / 70 | 13M | 6M |
| Q2 2024 | 1,334 | 103M | 99.2% | 125 / 547 | 430 / 84 | 5M | 5M |
| Q1 2024 | 1,310 | 104M | 100.0% | 149 / 483 | 449 / 96 | 8M | 3M |
| Q4 2023 | 1,273 | 100M | 96.6% | 186 / 441 | 443 / 68 | 13M | 4M |
| Q3 2023 | 1,178 | 91M | 88.2% | 111 / 400 | 447 / 88 | 4M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,008 funds held REGN in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of REGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,270,896 | 3.16% | $2.04B | 0.09% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 3,121,304 | 3.02% | $1.95B | 1.64% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,588,231 | 2.50% | $1.61B | 0.10% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2,186,867 | 2.11% | $1.36B | 0.28% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,374,351 | 1.33% | $856.96M | 0.10% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,289,978 | 1.25% | $793.05M | 0.10% | May 31, 2026 |
| Putnam Large Cap Value Fund | 1,152,014 | 1.11% | $878.56M | 1.59% | Jul 31, 2026 |
| Vanguard Mid-Cap Index Fund | 1,116,182 | 1.08% | $695.98M | 0.31% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,072,221 | 1.04% | $817.71M | 2.14% | Jul 31, 2026 |
| Vanguard Value Index Fund | 981,751 | 0.95% | $612.16M | 0.24% | Jun 30, 2026 |
| JPMorgan Equity Premium Income ETF | 752,509 | 0.73% | $469.22M | 1.05% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 727,411 | 0.70% | $453.57M | 0.31% | Jun 30, 2026 |
| iShares Biotechnology ETF | 715,060 | 0.69% | $445.87M | 4.91% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 705,889 | 0.68% | $440.15M | 1.08% | Jun 30, 2026 |
| College Retirement Equities Fund - Growth Account | 586,888 | 0.57% | $365.95M | 0.85% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| George Yancopoulos | Bd. Co-Chair, President & CSO, Director | 1,125,945 | 1.09% | Jan 5, 2026 |
| Leonard S. Schleifer | Bd. Co-Chair, President & CEO, Director | 2,442,116 | 2.36% | Jan 5, 2026 |
| Jason Pitofsky | SVP Controller | 4,320 | 0.00% | Nov 6, 2026 |
| Andrew J. Murphy | Co-Chief Scientific Officer | 51,193 | 0.05% | Nov 5, 2026 |
| Joseph J. Larosa | EVP General Counsel and Secret | 44,726 | 0.04% | Nov 4, 2026 |
| Christopher R. Fenimore | EVP Finance CFO | 25,249 | 0.02% | Nov 4, 2026 |
| Marion McCourt | EVP Commercial | 11,090 | 0.01% | Nov 3, 2026 |
| Plew Daniel P. Van | EVP & General Mgr, Industrial | 35,178 | 0.03% | Dec 11, 2025 |
| Neil Stahl | EVP Research and Development | 59,283 | 0.06% | Dec 18, 2024 |
| Huda Y. Zoghbi | Director | 1,703 | 0.00% | Nov 5, 2026 |
| Christine A. Poon | Director | 5,219 | 0.01% | Nov 4, 2026 |
| George L. Sing | Director | 27,297 | 0.03% | Nov 4, 2026 |
| Kathryn Guarini | Director | 603 | 0.00% | Nov 3, 2026 |
| Michael S. Brown | Director | 12,865 | 0.01% | Nov 3, 2026 |
| Arthur F. Ryan | Director | 17,303 | 0.02% | Jul 7, 2026 |
| Bonnie L. Bassler | Director | 3,203 | 0.00% | Jan 8, 2026 |
| N. Anthony Coles | Director | 1,714 | 0.00% | Jan 6, 2026 |
| David P. Schenkein | Director | 603 | 0.00% | Jan 6, 2026 |
| Craig B. Thompson | Director | 775 | 0.00% | Jan 6, 2026 |
| Joseph L. Goldstein | Director | 6,703 | 0.01% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −179 | $950.76 | $170.19K | 0 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −35 | $945.61 | $33.10K | 4,272 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −108 | $944.22 | $101.98K | 4,307 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −529 | $943.53 | $499.13K | 4,415 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −1,215 | $942.31 | $1.14M | 4,944 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −982 | $941.58 | $924.63K | 6,159 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −575 | $940.46 | $540.76K | 7,141 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Sale | −439 | $939.57 | $412.47K | 7,716 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Option exercise | +905 | $492.00 | $445.26K | 8,155 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Option exercise | +1,478 | $644.54 | $952.63K | 7,250 |
| Jason Pitofsky SVP Controller | Nov 4, 2026 | Option exercise | +1,500 | $726.53 | $1.09M | 5,772 |
| Andrew J. Murphy Co-Chief Scientific Officer | Nov 3, 2026 | Gift | −1,054 | – | – | 46,779 |
| Huda Y. Zoghbi Director | Nov 3, 2026 | Sale | −500 | $971.06 | $485.53K | 1,703 |
| Huda Y. Zoghbi Director | Nov 3, 2026 | Sale | −6,939 | $970.42 | $6.73M | 2,203 |
| Huda Y. Zoghbi Director | Nov 3, 2026 | Option exercise | +7,439 | $380.95 | $2.83M | 9,142 |
| Christopher R. Fenimore EVP Finance CFO | Nov 2, 2026 | Gift | −15 | – | – | 21,726 |
| Christopher R. Fenimore EVP Finance CFO | Nov 2, 2026 | Tax withholding | −4,243 | $950.50 | $4.03M | 21,741 |
| Christopher R. Fenimore EVP Finance CFO | Nov 2, 2026 | Option exercise | +6,000 | $381.92 | $2.29M | 25,984 |
| Joseph J. Larosa EVP General Counsel and Secret | Nov 2, 2026 | Sale | −527 | $966.11 | $509.14K | 38,906 |
| Joseph J. Larosa EVP General Counsel and Secret | Nov 2, 2026 | Sale | −3,939 | $965.41 | $3.80M | 39,433 |
| Joseph J. Larosa EVP General Counsel and Secret | Nov 2, 2026 | Tax withholding | −8,686 | $950.50 | $8.26M | 43,372 |
| Joseph J. Larosa EVP General Counsel and Secret | Nov 2, 2026 | Option exercise | +12,283 | $381.92 | $4.69M | 52,058 |
| George L. Sing Director | Nov 2, 2026 | Sale | −200 | $970.18 | $194.04K | 25,147 |
| George L. Sing Director | Nov 2, 2026 | Sale | −1,040 | $967.07 | $1.01M | 25,347 |
| George L. Sing Director | Nov 2, 2026 | Sale | −1,522 | $966.27 | $1.47M | 26,387 |
| George L. Sing Director | Nov 2, 2026 | Sale | −7,073 | $965.38 | $6.83M | 27,909 |
| George L. Sing Director | Nov 2, 2026 | Sale | −2,670 | $964.57 | $2.58M | 34,982 |
| George L. Sing Director | Nov 2, 2026 | Sale | −4,338 | $963.47 | $4.18M | 37,652 |
| George L. Sing Director | Nov 2, 2026 | Sale | −2,522 | $962.61 | $2.43M | 41,990 |
| George L. Sing Director | Nov 2, 2026 | Sale | −540 | $961.85 | $519.40K | 44,512 |
| George L. Sing Director | Nov 2, 2026 | Sale | −1,224 | $960.57 | $1.18M | 45,052 |
| George L. Sing Director | Nov 2, 2026 | Option exercise | +7,439 | $380.95 | $2.83M | 46,276 |
| George L. Sing Director | Nov 2, 2026 | Option exercise | +7,830 | $376.69 | $2.95M | 38,837 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −201 | $971.31 | $195.23K | 5,219 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −937 | $970.51 | $909.37K | 5,420 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −3,203 | $969.50 | $3.11M | 6,357 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −2,499 | $968.58 | $2.42M | 9,560 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −772 | $967.38 | $746.82K | 12,059 |
| Christine A. Poon Director | Nov 2, 2026 | Sale | −218 | $966.74 | $210.75K | 12,831 |
| Christine A. Poon Director | Nov 2, 2026 | Option exercise | +7,830 | $376.69 | $2.95M | 13,049 |
| Kathryn Guarini Director | Oct 30, 2026 | Sale(10b5-1 plan) | −400 | $900.00 | $360.00K | 603 |
| Kathryn Guarini Director | Oct 30, 2026 | Option exercise | +400 | $719.37 | $287.75K | 1,003 |
| Marion McCourt EVP Commercial | Oct 30, 2026 | Sale(10b5-1 plan) | −1,132 | $869.43 | $984.19K | 10,871 |
| Michael S. Brown Director | Oct 30, 2026 | Sale(10b5-1 plan) | −1,929 | $875.00 | $1.69M | 1,380 |
| Michael S. Brown Director | Oct 30, 2026 | Option exercise | +1,929 | $725.89 | $1.40M | 3,309 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −50 | $781.47 | $39.07K | 47,833 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −463 | $780.63 | $361.43K | 47,883 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −380 | $779.59 | $296.24K | 48,346 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −454 | $778.64 | $353.50K | 48,726 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −38 | $777.76 | $29.55K | 49,180 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −66 | $776.31 | $51.24K | 49,218 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −376 | $775.46 | $291.57K | 49,284 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −121 | $774.48 | $93.71K | 49,660 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −224 | $773.40 | $173.24K | 49,781 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −211 | $772.56 | $163.01K | 50,005 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −283 | $771.56 | $218.35K | 50,216 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −12 | $770.20 | $9.24K | 50,499 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −127 | $769.30 | $97.70K | 50,511 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −105 | $768.33 | $80.67K | 50,638 |
| Andrew J. Murphy Co-Chief Scientific Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −192 | $767.39 | $147.34K | 50,743 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.23%
2M shares short
Days to cover
2.7
At 1M shares a day
Change since last report
+3.8%
From 2M shares
Short volume, 20 days
47.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regeneron Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,016 shares on Aug 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jason Pitofsky Officer | Nov 4, 2026 | 3,883 | $3.79M | Nov 4, 2026 | stock option grant |
| Jason Pitofsky Officer | Nov 4, 2026 | 180 | $175.20K | Nov 4, 2026 | Inherited |
| Huda Y. Zoghbi Director | Nov 3, 2026 | 7,439 | $7.22M | Nov 3, 2026 | stock option exercise |
| Christine A. Poon Director | Nov 2, 2026 | 7,830 | $7.53M | Nov 2, 2026 | Acquired as compensation -- Stock Options |
| George L. Sing Director | Nov 2, 2026 | 21,129 | $20.38M | Nov 2, 2026 | Exercise of Options Under a Registered Plan |
| Joseph J. Larosa Officer | Nov 2, 2026 | 4,466 | $4.31M | Nov 2, 2026 | Stock Option Exercise |
| Kathryn Guarini Director | Oct 30, 2026 | 400 | $360.00K | Oct 30, 2026 | Exercise of stock option |
| Michael S. Brown Director | Oct 30, 2026 | 1,929 | $1.58M | Oct 30, 2026 | Exercise of Stock Options |
| Marion McCourt Officer | Oct 30, 2026 | 1,132 | $984.19K | Oct 30, 2026 | RSA Vesting |
| Andrew J. Murphy Officer | Oct 14, 2026 | 4,147 | $3.20M | Oct 14, 2026 | Exercise of Stock Options |
| Marion McCourt Officer | Sep 3, 2026 | 1,131 | $969.27K | Sep 3, 2026 | RSA Vesting |
| Kathryn Guarini Director | Sep 2, 2026 | 400 | $340.00K | Sep 2, 2026 | Exercise of stock option |
| Marion McCourt Officer | Sep 2, 2026 | 1,215 | $1.03M | Sep 2, 2026 | RSA Vesting |
| Kathryn Guarini Board member | Aug 10, 2026 | 400 | $320.00K | Aug 10, 2026 | Exercise of stock option |
| Huda Y. Zoghbi Director | Aug 10, 2026 | 800 | $640.00K | Aug 10, 2026 | Exercise of stock options |
See a number that looks wrong?